Molnupiravir is an experimental antiviral drug which is orally active and was developed for the treatment of influenza. It is a prodrug of the synthetic nucleoside derivative N4-hydroxycytidine, and exerts its antiviral action through introduction of copying errors during viral RNA replication.

Merck Announces Supply Agreement with U.S. Government.

Will its trial data be as wrong as remdesivir and bamlanivimab were?


Linked below is a discussion of the mutagenic risk of Molnupiravir in an in vitro study.

https://academic.oup.com/jid/advance-article/doi/10.1093/infdis/jiab247/6272009